Corcept Therapeutics Incorporated

CORT

Medical - Pharmaceuticals · Healthcare

Price

$90.52

+0.80 (+0.89%)

Market Cap

$9.72B

Exchange

NASDAQ

Winston Score

Winston is serious

Mixed quality — meaningful strengths and weaknesses.

Share count falling — buybacks

−4.7% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 126.0M (2021) → 120.0M (2025)

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.

Winston Score History

Politician Trades

4 trades / 12mo

2 Congressional buys and 2 sells on CORT in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+4.9% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

-257.9% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$255M/ year

→ Flat (+3% vs prior year)

33.5% of revenue

1.9x the sector average (18%)

Steady R&D investment year-over-year

Insider Activity

16.3%ownership

Insiders own a meaningful stake in the company

Cash Runway

~19 months

$109M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Adequate runway but may need to raise capital within 2 years

Growth context

Corcept Therapeutics Incorporated is growing revenue at 5% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

98.3%

Premium pricing power — 98.3% gross margin

Operating Margin

-30.1%

Losing money on operations — -30.1%

ROCE

-7.7%

Weak — -7.7% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+12.2%

Fast-growing sales (12.2% YoY)

EPS YoY

-64.6%

Earnings shrinking (-64.6% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

251%

Turns 251% of profit into real cash

FCF Margin

15.6%

Converts sales into free cash efficiently (15.6%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.02

Conservative — low debt load (0.02)

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

201.2x

Expensive — P/E 201.2

P/E over 35. The market is pricing in heavy, sustained growth.

P/E vs Forward

+184.5

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (201.2 → 16.7)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial